Cisplatin chemotherapy (without erythropoietin) and risk of life-threatening thromboembolic events in carcinoma of the uterine cervix: the tip of the iceberg? A review of the literature

Table 2 Incidence of thromboembolic toxicity in prospective studies using cisplatin

Trial	Chemotherapy	XRT	Toxicity	No. CTX Pts
Keys et al. [5] (cervix)	Cis 40 mg/m² q wk X 6 concurrent	75 Gy to pt A	0 deaths 1 Grade 3&1 Grade 4 CVT (NOS)	183
Benedetti et al. [3] (cervix)	Cis 40–80 mg/m² q wk X 6–8 concurrent	45–50 Gy WP 20–30 Gy Low Dose Rate	0 deaths	201
Morris et al. [2] (cervix)	Cis 75 mg/m² and 5-FU 4000 mg/m² q wk X 3 concurrent	85 Gy to pt A	1 death (NOS)	193
Pearcey et al. [6] (cervix)	Cis 40 mg/m² q wk X 5 concurrent	80 Gy to pt A	1 death (SBP) 3 Grade 3 CVT (NOS)	127
Peters et al. [7] (cervix)	Cis 70 mg/m² and 5-FU 1000 mg/m² q wk X 4 concurrent	4930 WP @ 170 cGy/day	1 death (Bilateral ureteral obstruction)	127
Rose et al. [8] (cervix)	Cis 40 mg/m² q wk X 6 concurrent or Cis/5-FU/Hydroxyurea or Hydroxyurea	80 Gy to pt A	0 deaths 2 Grade 3 CVT (NOS), with 3 drug regimen	526
Malfetano et al. [4] (cervix)	Cis 1 mg/Kg q wk with XRT	45 Gy PA, WP 4–5000 cGy and 3–4000 cGy Low Dose Rate	2 Grade 5 CVT (from PE)	67

NOS = Not otherwise specified CVT = Cardiovascular Toxicity SBP: Small Bowel Perforation Cis = Cisplatin 5FU = 5 Fluorouracil WP = Whole Pelvis Gy = Gray

ISSN: 1748-717X